Cabotegravir
Cabotegravir is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including Apretude. Available dosage forms: kit, powder.
Drug details
- Generic Name
- Cabotegravir
- Brand Names
- Apretude
- Application Number
- NDA215499
- Sponsor
- ViiV Healthcare Company
- NDC Codes
- 4
- Dosage Forms
- KIT, POWDER
- Active Ingredients
- CABOTEGRAVIR
Indications and Usage
1 INDICATIONS AND USAGE APRETUDE is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP [see Dosage and Administration ( 2.2 , 2.4 ), Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . APRETUDE is an HIV-1 integrase strand transfer inhibitor (INSTI) indicated for PrEP to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP. ( 1 )